-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $300

Benzinga·04/07/2026 12:55:21
Listen to the news
Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $375 to $300.